Table 3 Anticancer activity screening results.

From: Design and efficient synthesis of pyrazoline and isoxazole bridged indole C-glycoside hybrids as potential anticancer agents

Compds

Cell Viability (%) ± SD

MCF-7

MDA-MB-453

MCF-10A

25 µM

10 µM

1 µM

25 µM

10 µM

1 µM

25 µM

50 µM

100 µM

9

53.7 ± 4.0

62.3 ± 3.6

79.7 ± 1.18

96.1 ± 35.7

76.4 ± 5.4

80.6 ± 8.0

87.6 ± 1.5

81.3 ± 2.9

84.2 ± 3.0

14

66.8 ± 3.0

69.8 ± 1.8

100.0 ± 4.5

65.3 ± 5.8

82.2 ± 11.5

80.8 ± 3.2

86.8 ± 2.8

84.6 ± 0.7

80.0 ± 1.5

20

47.3 ± 7.6

58.7 ± 2.4

79.2 ± 2.6

66.4 ± 3.2

74.8 ± 1.5

105 ± 8.1

85.8 ± 5.3

78.8 ± 3.0

36.5 ± 3.4

25

19.9 ± 2.9

34.0 ± 2.5

66.0 ± 4.7

69.6 ± 5.3

78.3 ± 4.7

88.8 ± 5.2

87.6 ± 2.2

84.6 ± 1.7

82.4 ± 2.6

34

23.1 ± 4.4

28.4 ± 0.9

41.3 ± 3.1

66.8 ± 1.7

80.9 ± 1.2

92.5 ± 4.6

87.6 ± 1.5

80.1 ± 2.8

84.2 ± 3.0

37

19.1 ± 3.5

21.2 ± 3.8

30.8 ± 4.2

96.1 ± 35.7

76.4 ± 5.4

95.4 ± 4.8

86.8 ± 2.8

83.2 ± 5.8

81.0 ± 1.5

YM155 (20 nM)

37.2 ± 1.7

37.2 ± 1.7

37.2 ± 1.7

33.2 ± 1.5

33.2 ± 1.5

33.2 ± 1.5

48.2 ± 1.6

48.2 ± 1.6

48.2 ± 1.6

Back to article page